claim: novartis to sponsor large clinical trial of hydroxychloroquine in hospitalized covid-19 patients
evidence_1: in addition to hydroxychloroquine, novartis plans to sponsor or co-sponsor clinical trials to study ruxolitinib and canakinumab for hospitalized patients with covid-19 infections.", "the clinical trial complements a commitment by novartis, through sandoz, to donate up to 130 million tablets of hydroxychloroquine to supply global clinical research efforts in the event the medicine is proven beneficial for treatment of covid-19.")